- Conditions: Obesity; Overweight
Interventions: Drug: NB32; Drug: PBO; Behavioral: Weight Management Program
Sponsors: Orexigen Therapeutics, Inc; Orexigen Therapeutics, Inc
Not yet recruiting - verified May 2012 - Conditions: Type 2 Diabetes; Overweight; Obesity
Interventions: Behavioral: Weight Watchers modified program; Other: Standard Care group
Sponsors: Medical University of South Carolina; Medical University of South Carolina; Weight Watchers International
Recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Insulin glargine
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec; Drug: insulin glargine
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012 - Condition: Diabetic Complications
Interventions: Device: Prontosan; Device: Saline
Sponsors: B. Braun Medical Inc.; B. Braun Medical Inc.
Recruiting - verified May 2012 - Condition: Diabetic Neuropathy, Painful
Interventions: Drug: MK-6096; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Mild to Moderate Edema of Diabetic Legs
Interventions: Device: mild compression diabetic sock; Device: Standard diabetic sock
Sponsors: Rosalind Franklin University of Medicine and Science; Rosalind Franklin University of Medicine and Science; Madigan Army Medical Center
Recruiting - verified February 2012 - Condition: Type 2 Diabetes Mellitus
Intervention: Drug: Lixisenatide (AVE0010)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Device: Proteus Sustained Behavior Change system; Drug: Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)
Sponsors: Proteus Biomedical, Inc.; Proteus Biomedical, Inc.
Not yet recruiting - verified December 2011 - Conditions: Hypertension; Diabetes
Interventions: Drug: Placebo; Drug: Azilsartan medoxomil; Drug: Azilsartan medoxomil
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HOE 901 - Insulin glargine; Drug: HOE901 - Insulin glargine-new formulation
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HOE 901 - New formulation of insulin glargine; Drug: HOE 901 - Insulin glargine
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Diabetes Mellitus
Interventions: Behavioral: Pharmacist disease/medication management; Behavioral: Pharmacist-patient encounters; Behavioral: Pharmacist medication intensification and adherence support; Behavioral: Pharmacist communication with primary care physicians; Behavioral: Pharmacist documentation in electronic medical record; Behavioral: Health promoter-patient encounters in-person or by phone; Behavioral: Health promoter medication and lifestyle support; Behavioral: Health promoter communication with pharmacists
Sponsors: University of Illinois; University of Illinois; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2011 - Condition: Type 1 Diabetes
Interventions: Behavioral: Healthy Thinking In Teens; Other: Advanced Diabetes Education.
Sponsors: Children's Memorial Hospital; Children's Memorial Hospital
Recruiting - verified December 2011 - Conditions: Type 2 Diabetes Mellitus; Chronic Kidney Disease
Interventions: Drug: CTP-499; Drug: Placebo
Sponsors: Concert Pharmaceuticals; Concert Pharmaceuticals
Recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875; Drug: TAK-875; Drug: Glimepiride
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Insulin Glargine; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Comparator: Placebo; Biological: Insulin Glargine; Drug: Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: TAK-875; Drug: TAK-875
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Glargine; Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Gastroparesis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: 10mg TZP-102; Drug: 20mg TZP-102
Sponsors: Tranzyme, Inc.; Tranzyme, Inc.
Recruiting - verified April 2012 - Condition: Painful Diabetic Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Technosphere Insulin; Drug: Technosphere Inhalation Powder
Sponsors: Mannkind Corporation; Mannkind Corporation
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo matching with Saxagliptin; Drug: Metformin IR; Drug: Metformin XR; Drug: Saxagliptin; Drug: Saxagliptin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Not yet recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Glargine; Drug: LY2605541
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: linagliptin; Drug: BI 10773 linagliptin FDC; Drug: BI 10773 linagliptin FDC; Drug: high dose BI 10773 placebo; Drug: high dose BI 10773 placebo; Drug: high dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: linagliptin; Drug: linagliptin; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: low dose FDC placebo; Drug: low dose FDC placebo; Drug: low dose FDC placebo; Drug: linagliptin placebo; Drug: linagliptin placebo; Drug: linagliptin placebo; Drug: BI 10773; Drug: BI 10773 high dose; Drug: BI 10773 low dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Intervention: Drug: Exenatide
Sponsors: University of Chicago; University of Chicago
Recruiting - verified August 2011 - Condition: Diabetes Mellitus, Type 2
Intervention:
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Diabetic Nephropathy; Chronic Kidney Disease
Interventions: Drug: Atrasentan; Drug: Placebo
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Conditions: Impaired Fasting Glucose; Impaired Glucose Tolerance
Intervention: Drug: Vitamin D
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified March 2012 - Conditions: Hypertension; Stage 2 Hypertension; Diabetes
Interventions: Drug: Valturna + amlodipine; Drug: valturna + placebo; Drug: Valturna + chlorthalidone
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Conditions: Cerebral Edema; Diabetic Ketoacidosis
Interventions: Other: Intravenous fluid; Other: intravenous fluid; Other: intravenous fluid; Other: Intravenous fluid
Sponsors: University of California, Davis; University of California, Davis; Children's Hospital of Philadelphia; Washington University School of Medicine; University of Utah; Children's Research Institute; Children's Hospital Boston; Columbia University; University of Colorado, Denver; Nationwide Children's Hospital; Children's Memorial Hospital; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI1356 low dose; Drug: placebo; Drug: BI1356 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Diabetes; Diabetic Retinopathy
Intervention: Behavioral: Diabetes Education
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012 - Condition: Diabetic Peripheral Neuropathic Pain
Interventions: Drug: BMS-954561; Drug: Pregabalin; Drug: BMS-954561; Drug: Placebo matching BMS-954561; Drug: Placebo matching Pregabalin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Sitagliptin 100mg; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Diabetes
Interventions: Behavioral: Picture good health/Imaginate una buena salud; Behavioral: Diabetes lecture
Sponsors: University of Chicago; University of Chicago; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2011 - Condition: Diabetes Mellitus, Type 1
Intervention: Biological: Autologous Hematopoietic Stem Cell Transplantation
Sponsors: Northwestern University; Richard Burt, MD; University of Sao Paulo General Hospital
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol for oral suspension placebo proxy; Drug: Welchol for oral suspension
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified April 2012 - Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Bardoxolone Methyl: 20 mg
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepride placebo; Drug: linagliptin placebo; Drug: linagliptin; Drug: glimepiride
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: liraglutide; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin; Drug: Placebo (Saxagliptin); Drug: Metformin IR; Drug: Placebo (Metformin); Drug: Metformin (Active Rescue)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Conditions: Nutritional and Metabolic Diseases; Inflammation; Physiological Phenomena
Interventions: Dietary Supplement: Placebo; Dietary Supplement: 10G; Dietary Supplement: 20G; Dietary Supplement: 40G; Dietary Supplement: Placebonofiber
Sponsors: Institute for Food Safety and Health, United States; Institute for Food Safety and Health, United States; California Strawberry Commission
Recruiting - verified January 2012 - Conditions: Medication Understanding; Diabetes; Hypertension
Intervention: Other: Enhanced Label
Sponsors: Northwestern University; Northwestern University; Agency for Healthcare Research and Quality (AHRQ)
Recruiting - verified July 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Pioglitazone 15 mg; Drug: Pioglitazone 45 mg; Drug: Pioglitazone 30 mg; Drug: BI 1356 / Pioglitazone 15 mg FDC; Drug: BI 1356; Drug: BI 1356 / Pioglitazone 30 mg FDC; Drug: BI 1356 / Pioglitazone 45 mg FDC
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified April 2012 - Conditions: Diabetes; Sleep Apnea
Interventions: Device: CPAP mask; Drug: Placebo
Sponsors: University of Chicago; University of Chicago
Recruiting - verified July 2010 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Exenatide Once Weekly; Drug: Placebo
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified December 2011 - Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Diabetic Foot Ulcers
Interventions: Drug: Santyl; Other: White Petrolatum
Sponsors: Healthpoint; Healthpoint
Recruiting - verified December 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 high dose; Drug: Placebo BI 10773 high dose; Drug: BI 10773 low dose; Drug: BI 10773 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Cystic Fibrosis Related Diabetes
Intervention:
Sponsors: Johns Hopkins University; Johns Hopkins University; Cystic Fibrosis Foundation; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Minnesota - Clinical and Translational Science Institute; Vanderbilt University; Northwestern University; Emory University
Recruiting - verified June 2011 - Condition: Diabetes Mellitus
Interventions: Drug: BGP-15 100 mg QD; Drug: BGP-15 100 mg BID; Drug: Placebo BID; Drug: BGP-15 200 mg QD; Drug: BGP-15 200 mg BID; Drug: BGP-15 400 mg QD
Sponsors: N-Gene Research Laboratories, Inc.; N-Gene Research Laboratories, Inc.; Integrium; Msource Medical Development GmbH; Kinexum LLC; Thermo Fisher Scientific; Haupt Pharma Wülfing GmbH; BARC nv
Recruiting - verified June 2011 - Condition: Foot Ulcer, Diabetic
Interventions: Device: Integra® Dermal Regeneration Template; Other: Conventional Wound Therapy
Sponsors: Integra LifeSciences Corporation; Integra LifeSciences Corporation
Recruiting - verified August 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012 - Conditions: Vitreous Hemorrhage; Proliferative Diabetic Retinopathy
Interventions: Drug: Ranibizumab; Behavioral: Saline
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI)
Recruiting - verified February 2012 - Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Condition: Diabetic Neuropathy
Interventions: Behavioral: Exercise; Behavioral: Exercise
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified April 2012 - Conditions: Type 2 Diabetes; Renal Insufficiency
Interventions: Drug: Glargine & glulisine; Drug: Glargine & glulisine
Sponsors: Loyola University; Loyola University; Sanofi-Aventis
Recruiting - verified September 2011 - Conditions: Type 1 Diabetes; Rejection of Pancreas Transplant; Desensitization
Intervention:
Sponsors: Northwestern University; Northwestern University; Northwestern Medical Foundation
Recruiting - verified August 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin phosphate; Drug: Placebo
Sponsors: Merck; Merck; Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: placebo tablets
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified January 2012 - Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Islets of Langerhans transplantation
Sponsors: University of Illinois; University of Illinois
Recruiting - verified August 2011 - Condition: Lipodystrophy
Intervention: Drug: metreleptin
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Condition: Type 2 Diabetes
Interventions: Drug: placebo; Drug: exenatide; Drug: exenatide
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified August 2011 - Conditions: Kidney Disease; Nephropathy; Type 2 Diabetes
Interventions: Drug: losartan; Drug: lisinopril; Drug: losartan
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2012 - Condition: Type 1 Diabetes Mellitus
Intervention: Procedure: Islet transplant
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2011 - Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Oral Insulin
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); National Center for Research Resources (NCRR); American Diabetes Association; Juvenile Diabetes Research Foundation
Recruiting - verified February 2012 - Conditions: Stroke; Myocardial Infarction; Diabetes
Interventions: Drug: pioglitazone; Drug: placebo
Sponsors: Yale University; Yale University; National Institute of Neurological Disorders and Stroke (NINDS); Takeda Pharmaceuticals North America, Inc.
Recruiting - verified August 2011
 |
Join Clinical Trials in Illinois for Diabetes |
